Generic Industry Consolidating But Still Mysterious
Executive Summary
Nearly 2,000 ANDAs remain unclaimed as US FDA begins fee calculations for GDUFA II.
You may also be interested in...
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
ANDA Approval Decline Continues, But Why?
US FDA says COVID disruptions may be having an impact; complete response letters have also dropped significantly.
ANDA Submissions Drop To Start FY2021
First quarter submission volume is the second lowest of the GDUFA era, in part because of BE study problems caused by the pandemic.